Abstract: Sickle cell anemia (SCA) is a genetic hemoglobinopathy marked by persistent hemolysis, vaso-occlusion, and many organ problems. Oxidative stress and inflammation are crucial in the pathophysiology of SCA, contributing significantly to disease severity and development. High levels of reactive oxygen species (ROS) and persistent inflammatory reactions worsen red cell sickling, endothelial dysfunction, and vascular damage. The present research gives a thorough overview of the processes that underpin inflammation and oxidative damage in SCA, emphasizing their interconnectedness and clinical significance. Hemolysis-induced ROS generation, redox imbalance, and antioxidant depletion disrupt cellular homeostasis, while Pro-inflammatory cytokines like interleukin-6 and tumor necrosis factor-α promote immunological activation and leukocyte adherence. Diagnostic approaches involving oxidative and inflammatory biomarkers are gaining clinical relevance for disease monitoring and therapeutic guidance. Current therapeutic strategies focus on antioxidant agents like Vitamin E and N-acetylcysteine, disease-modifying drugs such as hydroxyurea, and lifestyle interventions to mitigate oxidative damage. Anti-inflammatory drugs, statins, omega-3 fatty acids, and new biologics are all being investigated for their capacity to reduce chronic inflammation. Advanced techniques, including genetic treatment approaches and stem cell-based transplants, show promise for therapeutic outcomes. Future research should emphasize personalized treatment approaches, integrative antioxidant and anti-inflammatory therapies, and the implementation of large-scale, long-term clinical trials to establish efficacy and safety. Addressing these gaps is critical for establishing focused, patient-specific interventions that can greatly improve the quality of life and clinical outcomes for people with SCA.
Afzal et al. (Mon,) studied this question.